Answers are grounded in this paper and cite their sources.
Randomized trial assesses bioequivalence of metformin/pioglitazone tablets in healthy Chinese subjects, indicating favorable results for both conditions.
were within acceptable bioequivalence limits (0.80-1.25), and no serious adverse events were observed. The study demonstrated that the tested and reference formulations of metformin/pioglitazone tablets are bioequivalent and well tolerated under both fasting and fed conditions.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: